May 2012
Three-Component Domino Reaction in PPG: An Easy Access to
4-Thiazolidinone Derivatives
631
1111, 1063, 1012, 855, 754, 721 cmÀ1
;
1H NMR (300 MHz,
= 8.48 (s, 1H, ArH), 8.07 (s, 1H, ArH), 7.62 (dd, J1 = 6.88 Hz,
J2 = 2.28 Hz, 2H, ArH), 7.44 (dd, J1 = 6.64 Hz, J2 = 2.08 Hz,
2H, ArH), 7.33 (dd, J1 = 6.88 Hz, J2 = 2.08 Hz, 2H, ArH), 7.19
(dd, J1 = 6.63 Hz, J2 = 1.84 Hz, 2H, ArH), 6.12 (s, 1H, CH),
3.98 (dd, J1 = 15.9 Hz, J2 = 1.6 Hz, 1H, CH2), 3.90 (dd, J1 =
15.8 Hz, J2 = 0.68 Hz, 1H, CH2) ppm; 13C NMR (100 MHz,
CDCl3): d = 171.03, 152.72, 140.99, 137.97, 136.97, 135.24,
132.31, 128.77, 126.63, 123.25, 120.60, 64.65, 35.51 ppm; MS
(ESI): m/z 401 [M]+; Anal. calcd for C17H13BrN4OS.0.51H2O:
C, 49.74; H, 3.44; N, 13.65; S, 7.81. Found: C, 50.11; H, 3.66;
N, 13.25; S, 7.63.
CDCl3): d = 8.04 (s, 1 H, ArH), 7.95 (s, 1H, ArH), 7.57 (d,
J = 8.4 Hz, 2H, ArH), 7.40 (d, J = 8.1 Hz, 2H, ArH),
7.26–7.16 (m, 4H, ArH), 6.14 (s, 1H, CH), 5.27 (s, 2H, CH2),
3.98 (dd, J1 = 16.0 Hz, J2 = 0.9 Hz, 1H, CH2), 3.87 (d, J =
15.9 Hz, 1H, CH2) ppm; 13C NMR (100 MHz, CDCl3): d =
170.85, 152.04, 143.29, 143.08, 137.32, 133.48, 128.52,
126.93, 125.98, 125.95, 125.38, 124.88, 64.27, 52.55, 33.13
ppm; MS(ESI): m/z 405 [M+H]+; Anal. calcd for
C19H15F3N4OS.H2O.0.4C6H6: C, 56.66; H, 4.31; N, 12.35; S,
7.07. Found: C, 56.43; H, 4.39; N, 12.35; S, 7.43.
3-(4-((1H-1,2,4-Triazol-1-yl)methyl)phenyl)-2-p-tolylthia-
zolidin-4-one (4c).
(Nujol): υ = 1686, 1610, 1560, 1513, 1426, 1414, 1376, 1336,
3-(4-((1H-Imidazol-1-yl)methyl)phenyl)-2-(2-(trifluorome-
thyl)phenyl)thiazolidin-4-one (4h). Gummy yellow solid; IR
(CHCl3): υ = 1693, 1608, 1515, 1455, 1392, 1313, 1271, 1232,
Light yellow solid; m.p. 138ꢀC. IR
1165, 1118, 1059, 1038, 906, 816, 761, 724, 662, 612 cmÀ1
;
1301, 1272, 1214, 1180, 1137, 1017, 957, 900, 829, 752, 679
cmÀ1 1H NMR (300 MHz, CDCl3): d = 8.06 (s, 1 H, ArH),
;
1H NMR (400 MHz, CDCl3): d = 7.61 (d, J = 8.04 Hz, 1H,
ArH), 7.56–7.54 (m, 2H, ArH), 7.47 (s, 1H, ArH), 7.38–7.37
(m, 1H, ArH), 7.27–7.25 (m, 2H, ArH), 7.06–7.04 (m, 3H,
ArH), 6.83 (s, 1H, ArH), 6.55 (s, 1H, CH), 5.03 (s, 2H, CH2),
3.99 (dd, J1 = 16.1 Hz, J2 = 1.32 Hz, 1H, CH2), 3.86 (d, J =
16.1 Hz, 1H, CH2) ppm; MS (ESI): m/z 404 [M+H]+.
7.93 (s, 1H, ArH), 7.18–7.09 (m, 8H, ArH), 6.06 (s, 1H, CH),
5.23 (s, 2H, CH2), 3.95 (d, J = 15.9 Hz, 1H, CH2), 3.82 (d,
J = 15.3 Hz, 1H, CH2), 2.36 (s, 3H, CH3) ppm; 13C NMR
(100 MHz, CDCl3): d = 171.03, 151.91, 143.02, 138.82,
137.66, 135.97, 133.00, 129.50, 128.32, 126.52, 125.66,
64.99, 52.60, 33.27, 21.02 ppm; MS (ESI): m/z 351 [M+H]+.
3-(4-(1H-Imidazol-1-yl)phenyl)-2-phenylthiazolidin-4-one
(4i). Yellow solid; m.p. 136ꢀC. IR (CHCl3): υ = 1688, 1682,
1607, 1520, 1490, 1456, 1431, 1382, 1344, 1303, 1265, 1247,
1219, 1178, 1131, 1111, 1074, 1056, 1029, 964, 904, 838, 816,
3-(4-((1H-1,2,4-Triazol-1-yl)methyl)phenyl)-2-(4-chlorophe-
nyl)thiazolidin-4-one (4d).
(Nujol): υ = 1686, 1514, 1491, 1376, 1272, 1216, 1137, 1089,
1015, 957, 844, 798, 752, 679 cmÀ1 1H NMR (300 MHz,
Yellow solid; m.p. 164ꢀC. IR
1
743, 700, 659 cmÀ1; H NMR (400 MHz, CDCl3): d = 7.75 (s,
;
CDCl3): d = 8.03 (s, 1 H, ArH), 7.94 (s, 1H, ArH), 7.25–7.17
(m, 8H, ArH), 6.07 (s, 1H, CH), 5.27 (s, 2H, CH2), 3.96 (d, J =
15.9 Hz, 1H, CH2), 3.85 (d, J = 15.6 Hz, 1H, CH2) ppm; MS
(ESI): m/z 371 [M+H]+.
1H, ArH), 7.32–7.30 (m, 9H, ArH), 7.17 (d, J = 8.24 Hz, 2H,
ArH), 6.12 (s, 1H, CH), 4.00 (dd, J1 = 15.91 Hz, J2 = 1.37 Hz,
1H, CH2), 3.89 (dd, J1 = 15.9 Hz, J2 = 0.69 Hz, 1H, CH2) ppm;
13C NMR (100 MHz, CDCl3): d = 170.69, 138.61, 136.08,
134.93, 130.01, 128.68, 128.60, 126.50, 126.30, 121.25,
117.55, 64.73, 32.98 ppm; MS (ESI): m/z 322 [M+H]+; Anal
calcd for C18H15N3OS.0.25H2O: C, 66.34; H, 4.79; N, 12.89; S,
9.84. Found: C, 66.55; H, 4.75; N, 12.73; S, 10.13.
3-(4-((1H-1,2,4-Triazol-1-yl)methyl)phenyl)-2-(3-chlorophe-
nyl)thiazolidin-4-one (4e).
White solid; m.p. 148ꢀC. IR
(Nujol): υ = 1690, 1513, 1477, 1432, 1375, 1328, 1273, 1244,
1199, 1137, 1078, 1017, 999, 957, 883, 855, 798, 750, 700, 680,
1
665, 634 cmÀ1; H NMR (400 MHz, CDCl3): d = 8.01 (s, 1 H,
3-(4-(1H-Imidazol-1-yl)phenyl)-2-(4-bromophenyl)thiazoli-
din-4-one (4j). Light yellow solid; m.p. 126ꢀC. IR (CHCl3): υ
= 1688, 1520, 1488, 1409, 1379, 1303, 1263, 1247, 1218, 1111,
ArH), 7.95 (s, 1H, ArH), 7.27–7.13 (m, 8H, ArH), 6.04 (s, 1H,
CH), 5.27 (s, 2H, CH2), 3.98 (dd, J1 = 16.0 Hz, J2 = 1.37 Hz,
1H, CH2), 3.85 (d, J = 16.0 Hz, 1H, CH2) ppm; 13C NMR (100
MHz, CDCl3): d = 171.02, 152.26, 143.32, 141.57, 137.54,
134.89, 133.66, 130.41, 129.29, 128.69, 126.95, 125.76, 124.99,
64.56, 52.73, 33.35 ppm; MS (ESI): m/z 371 [M+H]+; Anal.
calcd for C18H15ClN4OS.0.25H2O: C, 57.60; H, 4.16; N, 14.93;
S, 8.54. Found: C, 57.68; H, 4.10; N, 14.79; S, 8.74.
1
1071, 1056, 1010, 964, 904, 834, 799, 756, 681, 658 cmÀ1; H
NMR (400 MHz, CDCl3): d = 7.78 (s, 1H, ArH), 7.45 (dd, J1 =
6.53 Hz, J2 = 1.83 Hz, 2H, ArH), 7.33–7.28 (m, 4H, ArH),
7.21–7.17 (m, 4H, ArH), 6.10 (s, 1H, CH), 3.98 (dd, J1 = 15.9
Hz, J2 = 1.37 Hz, 1H, CH2), 3.89 (dd, J1 = 16.0 Hz, J2 = 0.69
Hz, 1H, CH2) ppm; 13C NMR (100 MHz, CDCl3): d = 170.87,
137.86, 136.18, 135.56, 135.27, 132.11, 130.37, 128.52,
126.65, 123.02, 121.89, 117.92, 64.50, 33.24 ppm; MS (ESI):
m/z 400 [M]+; Anal calcd for C18H14BrN3OS.0.4H2O: C, 53.05;
H, 3.66; N, 10.31; S, 7.87. Found: C, 53.10; H, 3.68; N, 9.98;
S, 7.89.
3-(4-((1H-1,2,4-Triazol-1-yl)methyl)phenyl)-2-(2-chlorophe-
nyl)thiazolidin-4-one (4f).
White solid; m.p. 142ꢀC. IR
(Nujol): υ = 1693, 1514, 1473, 1445, 1376, 1339, 1304, 1272,
1218, 1138, 1047, 1017, 957, 852, 800, 749, 698, 679, 610
cmÀ1 1H NMR (400 MHz, CDCl3): d = 8.00 (s, 1 H, ArH),
;
7.94 (s, 1H, ArH), 7.38–7.18 (m, 8H, ArH), 6.53 (s, 1H, CH),
5.27 (s, 2H, CH2), 3.92 (dd, J1 = 16.0 Hz, J2 = 1.37 Hz, 1H,
CH2), 3.79 (d, J = 16.0 Hz, 1H, CH2) ppm; 13C NMR (100
MHz, CDCl3): d = 171.42, 152.24, 143.19, 137.88, 136.79,
132.91, 132.41, 130.38, 129.89, 128.68, 127.62, 126.91, 124.29,
61.61, 52.82, 32.98 ppm; MS (ESI): m/z 371 [M+H]+; Anal.
calcd for C18H15ClN4OS.0.2H2O: C, 57.73; H, 4.15; N, 14.96;
S, 8.56. Found: C, 57.92; H, 4.43; N, 14.61, S, 8.54.
3-(4-Morpholinophenyl)-2-phenylthiazolidin-4-one (4k).
Pale yellow solid; m. p. 186ꢀC. IR (CHCl3): υ = 1682, 1608,
1516, 1450, 1379, 1341, 1303, 1263, 1234, 1176, 1121, 1072,
1051, 1029, 930, 826, 805, 786, 752, 705, 697, 657, 608
cmÀ1 1H NMR (400 MHz, CDCl3): d = 7.30–7.24 (m, 5H,
;
ArH), 7.01 (dd, J1 = 6.88 Hz, J2 = 1.84 Hz, 2H, ArH), 6.77
(dd, J1 = 7.09 Hz, J2 = 1.84 Hz, 2H, ArH), 5.98 (d, J = 1.84
Hz, 1H, CH), 3.99 (dd, J1 = 16.0 Hz, J2 = 1.84 Hz, 1H, CH2),
3.86(d, J = 16.0 Hz, 1H, CH2), 3.79 (t, J = 5.0 Hz, 4H,
morpholine), 3.08 (t, J = 5.0 Hz, 4H, morpholine) ppm; 13C
NMR (100 MHz, CDCl3): d = 171.19, 150.09, 129.26, 128.97,
127.08, 126.96, 115.79, 66.83, 65.99, 65.83, 48.90, 33.44
3-(4-(1H-1,2,4-Triazol-1-yl)phenyl)-2-(4-bromophenyl)thia-
zolidin-4-one (4g). Yellow solid; m. p. 128ꢀC. IR (CHCl3): υ
= 1686, 1521, 1489, 1375, 1278, 1144, 1071, 1051, 1009, 982,
1
954, 835, 771, 673, 567 cmÀ1; H NMR (400 MHz, CDCl3): d
Journal of Heterocyclic Chemistry
DOI 10.1002/jhet